These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 11176485)

  • 1. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
    Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
    J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score.
    Fine SW; Epstein JI
    J Urol; 2008 Apr; 179(4):1335-8; discussion 1338-9. PubMed ID: 18289601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
    Mol Urol; 2000; 4(3):171-5;discussion 177. PubMed ID: 11062371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
    Graefen M; Haese A; Pichlmeier U; Hammerer PG; Noldus J; Butz K; Erbersdobler A; Henke RP; Michl U; Fernandez S; Huland H
    J Urol; 2001 Mar; 165(3):857-63. PubMed ID: 11176486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting prostatic biopsy Gleason sum under grading.
    Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
    J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.